鲍曼不动杆菌感染的临床分布及耐药性分析

目的 了解鲍曼不动杆菌的临床分布及其对常用抗生素的耐药情况.方法 收集我院2007年7月至2010年7月的临床标本,进行鲍曼不动杆菌分离培养及药敏试验.结果 3年共分离出鲍曼不动杆菌373株,在临床标本中,痰液分布率最高,占78.6％,感染分布以ICU为主,占36.2％.药敏试验显示对碳青霉烯类、含酶抑制剂、多粘菌素E敏感性较高,对氨基糖苷类、喹诺酮类、β-内酰胺类耐药率较高,多重耐药性明显.结论 鲍曼不动杆菌主要侵犯ICU患者、慢性呼吸系统疾病患者及术后感染者.

Analysis on infection clinical distribution and drug resistance of acinetobacter baumannii

Objective To investigate the infection clinical distribution and drug resistance of acinetobacter baumannii,and to offer an aid for clinical therapy and control of hospital-acquired infection.Methods The clinical specimens were collected from July 2007 to July 2010 for performing isolation,culture and sensitivity test to Acinetobacter baumannii.Results 373 strains of Acinetobacter baumannii were isolated in three years,whose dietribution was the highest in the sputum(78.6%).The infection distribution was major in the intensive care unit(ICU),accounting for 36.2%.It was showed that the sensitive drugs of Acinetobacter baumannii were carbapenems,and inhibitor,polymyxin E,and resistant drugs of Acinetobacter baumannii were aminoglycosides,quinolones,and bets-lactamases.Moreover,these strains showed multi-drug resistance.Conclusion Acinetobacter baumannii mainly offended the patients in ICU and with chronic respiratory diseases and postoperative infection.Therefore,laboratories should be strengthened to analyze the resistant strains of Acinetobacter baumannii in wards,especially the ICU wards and drug sensitivity monitoring to provide relevant information in time,and antibiotics should be used rationally so as to enhance clinical therapeutic efficacy.